# mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

> **NCT03045770** · NA · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

## Interventions

- **DRUG:** Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Paclitaxel
- **DRUG:** calcium levofolinate

## Key facts

- **NCT ID:** NCT03045770
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-02-10
- **Primary completion:** 2019-12-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03045770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03045770, "mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03045770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*